The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: Good afternoon, gentlemen, and thank you for taking the questions. Maybe to kick things off, just a couple of items on Lumin.
Obviously, a nice jump in the number of users here this past quarter, up to 150. I'm just curious of what the feedback is from those customers that
have been onboard for maybe the past year, and what's driving some of the new adoption.
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: Got it. And then, it sounds like -- so you have added a new sales team specifically geared towards that Lumin platform. How many members are
on that team? Maybe what was your prior experience before joining Champions? And is some of their role going to be on the support side, or are
they purely out finding new customers?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
DECEMBER 13, 2021 / 9:30PM, CSBR.OQ - Q2 2022 Champions Oncology Inc Earnings Call
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: Got it. Okay. Maybe shifting gears a little bit. I've got two questions and then I'll hop back in the queue. First up, maybe you could update us on the
flow cytometry pipeline, how that's progressing.
And then, I guess the last question would be regarding the European lab that has officially opened as of -- or opened during the quarter. If you
could give us an update on how those discussions are going, and whether or not you've started to generate revenues out of that facility. Thank
you.
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: Understood. Great. Thank you very much for taking the questions.
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: Thank you, and good afternoon. Just a couple of questions. First, another strong sequential gain from first quarter to second quarter of fiscal '22.
Would you care to make any comments on the second half of the year? I believe we're thinking about sequential gains in the next two quarters as
well, perhaps even larger gains. Just any thoughts you have on that would be great.
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: Okay, perfect. Thank you. And then the gross margin of 52% in 2Q, do you expect -- I mean, that was a pretty good number. It was a pretty good
number in first quarter as well. Can we expect those levels to stay that high throughout the second half of the year?
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: Okay, great. And then, one more model question. I think R&D was $2.3 million in 2Q.
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: I believe you said it's going to step up in the second half of the year. What size and magnitude? Are we talking about couple hundred thousand
dollars per quarter here or larger than that?
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: Okay. But it sounds like that may be more pronounced in the fourth quarter than the third quarter. Did I hear that correct?
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: Okay, great. And then the final question, you mentioned the six targets in the proprietary pipeline. How should we think of the timeline to either
partner those programs or reach an inflection point? I mean, are we thinking a year out, or are we thinking two years out? Just trying to get a sense
of when we may see some catalysts on that front.
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: Okay, great. Thank you for taking the questions.
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: Sure.
| 
